Thu, 09 Jul 2015 13:09:13 GMT ~ Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia
[at noodls] - NOVATO, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
Thu, 09 Jul 2015 13:01:00 GMT ~ 9:01 am Ultragenyx Pharma announced positive interim data in the ongoing pediatric Phase 2 study for recombinant human monoclonal antibody KRN23
Thu, 09 Jul 2015 13:00:00 GMT ~ Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia
[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim ...
Link: http://www.otcmarkets.com/stock/RARE/company-info Ticker: $RARE OTC Market Place: Not Available CIK code: not found Company name: Ultragenyx Pharmaceutical Inc. Incorporated In:
$RARE share structure
## source: otcmarkets.com
Market Value: Not Available Shares Outstanding: Not Available Float: Not Available Authorized Shares: Not Available Par Value: Not Available